About Long R3 IGF-1

Mechanism of action: Long R3 IGF-1 is a synthetic analogue of insulin-like growth factor 1 (IGF-1) with a 13-amino-acid substitution that reduces binding to IGF-binding proteins, resulting in greater bioavailability and prolonged half-life compared with native IGF-1. It acts directly on IGF-1 receptors in peripheral tissues, stimulating anabolic effects such as increased protein synthesis, muscle growth, and fat metabolism, independently of growth hormone (GH) stimulation.

Indications & off-label uses: Long R3 IGF-1 was originally developed for research purposes and has no FDA-approved therapeutic indications. Off-label, it is sometimes used in private clinics or research settings to enhance lean body mass, improve recovery, support tissue repair, and potentially complement GH or GH secretagogue therapy. Evidence for efficacy in healthy adults for performance enhancement or anti-aging is limited.

FDA status & availability: Long R3 IGF-1 is not FDA-approved for clinical use and is typically available only through compounding pharmacies.

Safety & monitoring: Potential adverse effects include hypoglycemia, edema, joint pain, organomegaly, and possible tumor-promoting effects in patients at risk. Long-term safety data in adults using off-label or performance-enhancing doses are lacking. Close monitoring of blood glucose, IGF-1 levels, and overall metabolic health is recommended when using off-label.